The differences of the present set of guide-lines from those of the ATP III and NCEP-C are given in Tables 5 and 6 of the guidelines, respec-tively. On behalf of the NKF, we would like to acknowledge the considerable effort and contri-butions of all those who made these guidelines possible. ATP III builds on previous ATP reports and expands the indications for intensive cholesterol-lowering therapy in clinical practice. It should be noted that these guidelines are intended to inform, not replace, the physician's clinical judgment, which must ultimately determine the appropriate treatment for each Like its predecessors, ATP III, issued in May 2001, emphasizes the role of diet and exercise in decreasing the risk for developing CHD. Unlike the earlier versions, the revised guidelines advocate a more aggressive approach to testing and management of LDLC, with a new focus on CHD prevention The NCEP ATP-III Guidelines define LDL-C as the primary target of therapy. It also defines elevated serum triglycerides as a risk factor, along with low HDL-C. Obtaining a lipid profile in fasting state is necessary in order to make meaningful decisions. The ATP III guidelines maintain, on the basis of all the evidence, that the relation of cholesterol to CHD risk is qualitatively similar in women (and men) with and without The ATP III guidelines provide a practical tool, based on the Framingham Heart Study findings, for assessment of the 10-year risk for a National Cholesterol Education Program. ATP III Guidelines At-A-Glance. Quick Desk Reference. LDL Cholesterol - Primary Target of Therapy. ATP III Classification of Serum Triglycerides (mg/dL) 200 mg/dL after LDL goal is reached, set secondary goal for non-HDL cholesterol (total - HDL) 30 mg/dL NCEP ATP III Guidelines: Dyslipidemia Risk Stratification. NCEP ATP III Guidelines: Goals for Lipid-lowering Therapy. Kostner K. touchcardiology.com/files/article_pdfs/kostner.pdf.AccessedSeptember 9, 2011. ATP 3-60 uses joint terms where applicable. Selected joint and Army terms and definitions appear in both the glossary and the text. It has been reformatted to comply with the 2015 Doctrine Strategy. Chapter 1 discusses the targeting guidelines and philosophy associated with targeting techniques. The ATP III Guidelines did not specify Lp(a) as a target for intervention, but some advocates propose counting an elevated Lp(a) as an additional risk factor to help establish the target for LDL cholesterol levels. ATP III Guidelines At-A-Glance Quick Desk Reference LDL Cholesterol - Primary Target of Therapy <100 Optimal 100-129 Near optimal/above optimal 130-159 Borderline high 160-189 High >190 Very high Total Cholesterol <200 Desirable 200-239 Borderline high >240 High HDL Cholesterol <40 Low AACE 2017 Guidelines. American association of clinical endocrinologists and american college of endocrinology. of individuals with very low (<5%) risk o 30% reclassification of those classified as 5% to <10% risk according to ATP III o 29% reclassification of AACE 2017 Guidelines. American association of clinical endocrinologists and american college of endocrinology. of individuals with very low (<5%) risk o 30% reclassification of those classified as 5% to <10% risk according to ATP III o 29% reclassification of ATP III Classification of LDL, Total, and HDL Cholesterol (mg/dL). Identify presence of clinical atherosclerotic disease that confers high risk for coronary heart disease (CHD) events (CHD risk equivalent) High Blood C.